Most mortalities from liver disease and liver cancer worldwide are attributable to hepatitis B virus (HBV) and hepatitis C virus. Despite remarkable advances in the treatment of HBV over past decades, limited population-level data are available regarding its impact on burden of liver disease and liver cancer. Mortality data from liver disease and liver cancer were obtained from the national death certificate database of Korea, an HBV-endemic country, between 1999 and 2013, and were analyzed by Joinpoint analysis. For liver disease, number of annual deaths decreased by 62.3% (95% confidence interval [CI], 62.0-62.6), crude death rate (CDR) decreased by 64.6% (95% CI, 64.3-64.9) from 21.2 to 7.5 per 100,000 population, and age-standardized death rate (ADR) declined by 75.0% (95% CI, 74.7-75.3), between 1999 and 2013. In contrast, for liver cancer, number of annual deaths increased by 17.8% (95% CI, 17.6-18.0) and CDR increased by 10.2%
L iver disease and liver cancer are estimated to be accountable for over 2 million deaths every year, approximately 4% of all deaths worldwide. (1) Most mortalities from liver disease (including cirrhosis and viral hepatitis [VH] ) and liver cancer are attributable to hepatitis B virus (HBV) and hepatitis C virus (HCV). When combined, HBV and HCV accounted for 55.0% and 78.5% of liver diseaseand liver cancer-related mortality in 2013.
(1) The relative contribution of HBV and HCV to liver Abbreviations: AAPC, average annual percentage change; ADR, age-standardized death rate; AIR, age-standardized incidence rate; ALD, alcoholic liver disease; APC, annual percentage change; ASM, age-specific mortality; CDR, crude death rate; CHB, chronic hepatitis B; CI, confidence interval; CIR, crude incidence rate; GBD, global burden of disease; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICD, International Classification of Disease; KCCR, Korea Central Cancer Registry; KOSIS, Korean Statistical Information Service; LT, liver transplantation; NHIS-NSC, Korean National Health Insurance Service-National Sample Cohort; VH, viral hepatitis; WHO, World Health Organization; YLL, years of potential life lost. disease and liver cancer mortality varies widely with regions. (2) During the past decades, remarkable advances have been made in prevention and treatment of HBV and HCV, including implementation of the universal infantile HBV vaccination program and introduction of highly efficacious antiviral agents. (3) (4) (5) (6) Nonetheless, the number of global deaths attributable to VH increased by 63% between 1990 and 2013. (7) Systematic and comprehensive evaluation of long-term trends in cause-specific mortality at a population level is of paramount importance to elucidate population-level effectiveness of medical interventions and help understand the burden of a specific disease in order to guide health policy strategies. (8) However, limited populationlevel data are available regarding trends in mortality from liver disease and liver cancer. Therefore, we examined temporal trends in mortality from liver disease and liver cancer in an HBV-endemic population between 1999 and 2013.
Materials and Methods

DATA SOURCES
Mortality data and population estimates were obtained from the Korean Statistical Information Service (KOSIS), a central government organization for statistics. (9) KOSIS annually compiles information on death certificate from the entire population of South Korea into public-use death files, wherein the underlying cause of death is selected according to the International Classification of Disease (ICD)-10 coding at the time of death. Causes of death statistics were collected based on the Statistics Act and Act on Registration. The death registration rates are nearly complete, and of all the deaths registered in 2012, 98.3% were confirmed by a physician's diagnosis. (10) Based on the global burden of disease (GBD) 2010 Gastrointestinal Diseases expert group recommendations, (11) we obtained the annual number of deaths from liver disease, including VH (ICD-10 codes K71-K79 and B15-19) and liver cancer (ICD-10 code C22) for analysis. Deaths from alcoholic liver disease (ALD; ICD-10 code K70) were excluded from our analysis.
Global mortality data were obtained from the GBD 2015 Study for liver disease (including acute VH and cirrhosis) and for liver cancer secondary to HBV and HCV, for comparison purposes. (7, 12, 13) We limited the study period between 1999 and 2013 because the first antiviral agent for HBV, lamivudine, was approved in late 1998, with successive approval of other antiviral agents for HBV and HCV, and cancer incidence data from the entire population have been collected since 1999 in Korea. (14) Liver cancer incidence data were obtained from the Korea Central Cancer Registry (KCCR), a nationwide, prospective, population-based database for cancer incidence, covering the entire Korean population. (14) All newly diagnosed cancer cases are identified and registered in the KCCR by specially trained registry staffs since 1999. Data completeness and accuracy were ensured through rigorous training and certification of registry staffs and use of standardized software with internal data checks. Estimated completeness rates of KCCR incidence data have been >95% since 1999. (14) In addition, there was no serial change in the surveillance for hepatocellular carcinoma (HCC) by Korea practice guidelines over the past 15 years. (15) (16) (17) 
ARTICLE INFORMATION:
We obtained claims data regarding numbers of patients who were prescribed oral antiviral agents for HBV (lamivudine, adefovir, telbivudine, clevudine, entecavir, or tenofovir) from the national health insurance service database, which covers >99% of the entire Korean population. (18) Data on liver transplantation (LT) between 2000 and 2013 were derived from the Korean Network for Organ Sharing (http://konos.go. kr/).
This study was exempt from ethical review according to the rules of our institution because only government-issued, public-use data were analyzed; no individual identification information was included.
STATISTICAL ANALYSIS
Years of potential life lost (YLL; per 100,000 persons) were calculated to measure the quantity of premature deaths. We calculated YLL by multiplying the number of deaths in each age group by the reference life expectancy at the age of death in those who died in the age group. We used a reference life expectancy of 86.59 years, as recommended by the GBD 2015 Study which decided to use the same reference standard for males and females. (13) Crude death rate (CDR; per 100,000 persons) and crude incidence rate (CIR; per 100,000 persons) were obtained by dividing the number of events in each category by the mid-year population estimates for each year. We calculated age-standardized death rate (ADR; per 100,000 persons) and age-standardized incidence rate (AIR; per 100,000 persons) following direct standardization methods using the world population age standard by the World Health Organization (WHO). (1) The Joinpoint Regression Program (version 4.3.1.0; NCI, Bethesda, MD; https://surveillance.cancer.gov/ joinpoint/) was used to calculate annual percentage change (APC) and average APC (AAPC). Joinpoint regression analysis provides best-fitting linear associations between rate trends and time. Trends were considered statistically significant when there was a significant change in slope (Supporting Methods).
To elucidate differences in mortalities from liver disease and liver cancer by birth cohort, we analyzed agespecific mortality (ASM) by various birth cohorts consisting of age groups with 5-year intervals (starting from 20 to 24 to >85 years) and birth cohorts with 5-year intervals (starting from 1910-1914 to 1990-1995) . (19) R package of epitools was used to calculate the crude and age-standardized rates, and R software (version 3.31; www.r-project.org) was used for other analyses. All statistical tests were two-sided, and statistical significance was defined as P < 0.05.
SENSITIVITY ANALYSIS
To quantify the relative contributions of each etiology to deaths from liver disease and liver cancer, we performed a sensitivity analysis using the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC), which is a representative sample cohort from the entire Korean population since 2002 and is provided for research purpose. (20) The details and methods of the sensitivity analysis are described in the Supporting Materials.
Results
NUMBER OF DEATHS AND YLL
Between 1999 and 2013, the annual number of deaths attributable to liver disease decreased from 10,004 to 3,773 (62.3% reduction; 95% confidence interval [CI], 62.0-62.6), and YLL per 100,000 from liver disease decreased from 664.4 to 175.7 (73.6% reduction; 95% CI, 73.3-73.9; Table 1 ).
In contrast, the number of deaths from liver cancer increased from 9,682 to 11,405 (17.8% increase; 95% CI, 17.6-18.0; Table 1 ). YLL from liver cancer decreased by 11.1%; however, the proportion of YLL attributable to liver cancer in the total YLL of the entire population increased by 11.9%.
CDRs
For liver disease, CDR decreased from 21.2 to 7.5 per 100,000 persons (64.6% reduction; 95% CI, 64.3-64.9) between 1999 and 2013 ( Table 2 ). When deaths from alcohol-induced liver disease were included, the decrease in CDR for liver disease was 43.6% (95% CI, 43.3-43.9; Supporting Fig. S1 ). In contrast to Korean trends, global CDR for liver disease has been steady between 1999 and Deaths from alcohol-induced liver disease were excluded. Table 2 ). Consequently, Korean CDR for liver cancer remained 3 times higher than global estimate in 2013 (22.6 vs. 5.8).
When stratified by sex, CDR from liver disease for males and females decreased (from 33.2 to 9.5, males; from 9.1 to 5.4, females), whereas CDR from liver cancer for both sexes increased (from 31.5 to 33.3, males; from 9.4 to 11.8, females), between 1999 and 2013 (Supporting Tables S1-S2; Supporting Fig. S2 ).
AGE-STANDARDIZED DEATH RATES
Age-standardized death rates (ADRs) for liver disease in Korea decreased by 75.0% (95% CI, 74.7-75.3) from 24.0 to 6.0 per 100,000 persons between 1999 and 2013 ( Fig. 1B; Table 2 ). When deaths from alcohol-induced liver disease were included, the decrease in ADR was 60.0% (95% CI, 59.7-60.3; Supporting Fig. S3 ). ADRs for liver cancer decreased to a lesser extent (26.9% reduction; 95% CI, 26.6-27.2; from 24.5 to 17.9; Fig. 1B ; Table 2 ).
When stratified by sex, ADRs from liver disease decreased for males (from 40.8 to 8. 
INCIDENCE RATES OF LIVER CANCER
Temporal trends for liver cancer incidence were similar to those for liver cancer mortality. CIR of liver cancer increased from 28.2 per 100,000 in 1999 to 32.0 in 2013 (15.3% increase; 95% CI, 15.1-15.5; Fig. 1C ; Table 2 ). In contrast, AIR of liver cancer constantly decreased from 33.8 in 1999 to 24.5 in 2013 (27.5% decrease; 95% CI, 27.2-27.8).
When stratified by sex, CIR of liver cancer modestly increased and AIR decreased during the same period for males and females (Supporting Tables S5-S6 ; Supporting Fig. S5 ).
NUMBER OF PATIENTS RECEIVING ANTIVIRAL TREATMENTS
The annual number of patients receiving oral antiviral agents for HBV steeply increased for >100 times Fig. 2 and Supporting Fig. S6 ). Cumulatively, oral antiviral agents for HBV were prescribed for 1,148,297 patientyears. The annual number of patients receiving interferon-based treatment for HBV or HCV remained <2,000 throughout the study period.
The annual number of patients receiving LT in Korea increased from 205 in 2000 to 1,188 in 2013, which does not fully explain the decreased number of deaths from liver disease (Fig. 2) . Moreover, 209 (17.6%) of LTs in 2013 were performed in liver cancer patients.
MEAN AGE AT DEATH
The mean age at death from liver disease increased by 8.8 years (from 56.1 to 64.9 years) between 1999 and 2013 (Fig. 3) , which was significantly greater than 6.1 years (from 59.5 to 65.6 years) of increase from liver cancer (P 5 0.02) and 6.3 years (from 75.6 to 81.9 years) for the entire population during the same period (P 5 0.001).
SENSITIVITY ANALYSIS
To determine the relative contribution of each etiology to mortalities from liver disease or liver cancer, we performed a sensitivity analysis using NHIS-NSC. Although NHIS-NSC data were available since 2002, the CDRs and ADRs from NHIS-NSC had similar trends to those from entire Korean population (Supporting Fig. S7-S8 ). The analysis showed that the contribution of HBV to CDR from liver disease continuously decreased between 2003 and 2013, whereas that of HCV to CDR from liver disease appears to have been stable (Table 3 ; Fig. 4A ). In contrast, CDR from HBV-related liver cancer has increased during the same period and CDR from HCV-related liver cancer as well (Table 3 ; Fig. 4B) ; however, HBV-related death from liver cancer accounted for most of total deaths from liver cancer over the study period.
A multistate model analysis (Supporting Fig. S9 ) by using the NHIS-NSC database also showed the higher probability of liver cancer mortality than liver disease mortality in 63,378 subjects with chronic hepatitis B (CHB; Supporting 
BIRTH COHORT EFFECTS
For liver disease, ASM steeply decreased in more recent time periods in each birth cohort born between 1915 and 1965 (Supporting Fig. S11 ). The earlierborn cohorts had steeper decreases in ASM at older ages. For example, among those born in 1940, liver disease mortality rate was 74.1 at age 59 in 1999, but decreased to 25.3 at age 69 in 2009.
For liver cancer, in contrast to liver disease, ASM increased during more recent time periods for all birth cohorts below age 85 (Supporting Fig. S12 ). The 
Discussion
Our population-based study in a HBV-endemic country demonstrated that mortality from liver disease decreased by >60% from 1999 through 2013 by all measures. In contrast, liver cancer mortality, in terms of absolute number of annual deaths and CDR, has significantly increased during the same period. This dissociation of mortality trends between liver disease and liver cancer coincided with the steep increase in annual prescription of oral antiviral agents against HBV and increased life expectancy of patients with liver disease.
In May 2016, the WHO adopted the first-ever global hepatitis strategy aiming to reduce mortality from VH by 65% by 2030. (21) A recent modelling study for hepatitis B showed that this goal could be achieved by scaling up the available treatment of the patients. (22) In this modeling, none of the prevention strategies reduced the mortality in the short term, but population-wide treatment reduced death by 65% between 2015 and 2030, compared with the status quo. Our data on reduction in liver disease mortality are very close to this, apart from liver cancer mortality. (22) A major strength of this study is its data sources. We used a wide array of population-based data from various sources as we described in the Materials and Methods Analysis of the Korean NHIS-NSC.
FIG. 4.
Deaths from liver disease and liver cancer by underlying disease in the NHIS-NSC database.
section. Therefore, our data fulfill the expectation of the above modeling study by providing real-world data on population level. We excluded deaths from ALD from the primary analyses for liver disease mortality; there were no significant changes in the prevalence of chronic HBV (around 4.5%) and HCV (around 1.2%) infection among adults and in the treatment of HCV in Korea during the study period. (23, 24) Therefore, our findings could be explained by advancements in management of HBV. When death from ALD was included, the temporal trends in mortality from liver disease also showed similar pattern of decrease.
Although the universal HBV vaccination program has been successfully implemented for almost three decades in Korea, thus substantially reducing HBV prevalence among children and young adults, most liver disease-and liver cancer-related deaths occurred in unvaccinated middle-aged and elderly adults. Therefore, considering the birth cohort effect on HBV-related mortality from liver disease and liver cancer, the HBV vaccination program is deemed to have limited or no impact on our findings.
Since 1999, HBV management has substantially progressed in Korea, including successive approval and life-long reimbursement of oral antiviral agents. The number of patients receiving oral antiviral therapy for HBV precipitously increased since 1999 (Fig. 2) , and the hypothesis that this therapeutic approach may increase patient survival has been suggested by several observational studies. (4, 5, 25) A recent study from Taiwan, another HBV-endemic country, has reported 8% reduction in mortality from liver disease after reimbursement of antiviral therapy for HBV, (26) far less than that in our study. The difference may be originated from multiple factors. Compared with Korea, Taiwan has a higher prevalence of HCV, (2) and more strict and shorter reimbursement policy for oral antiviral agents for HBV. (26) A peculiar finding of our study was the dissociation of mortality trends between liver disease and liver cancer. Within the same birth cohort, age-specific rates of liver cancer-related death increased during more recent periods, a striking contrast to the markedly decreasing rate of mortality from liver disease with aging. HCC represents more than 90% of primary liver cancer. (27) Risk factors for liver disease and HCC overlap, and 72.8% of HCC cases in Korea occur in patients with chronic HBV infection. (2) Moreover, antiviral therapy for HBV does not completely remove the risk of HCC, particularly in patients with advanced fibrosis, and its disproportionate impact on the development of HCC and abatement of inflammation in the liver resulting from HBV-DNA suppression may exist. Marked decrease in liver disease mortality may increase the life expectancy and number of patients at risk of developing HCC, inadvertently leading to increased HCC incidence and mortality in the population. The greater increase in mean age at death from liver disease than that from liver cancer during our study period supports the explanation. Therefore, our data should be interpreted considering the competing nature between death from liver disease and that from liver cancer. Advanced hepatic fibrosis or cirrhosis is an independent risk factor for death from both liver disease and HCC in patients with chronic HBV and HCV infection. (5, 28, 29) Therefore, the competing risk of mortality between liver disease and liver cancer could be observed not only in HBV-endemic populations, but also in populations with high prevalence of chronic HCV infection.
One of the major findings of this study was the dissociation between crude rates and age-standardized rates for liver cancer mortality. Similar to our results, decreasing trends in ADR and increase in absolute number of deaths and CDR from liver cancer have also been observed in other HBV-endemic populations. (1, 7, 11, 13, 30) Plausible explanations may stem from population growth and aging. (13) Age-standardized rates ensure that differences in incidence or deaths between one geographical area and another are not attributed to differences in age distribution of the populations being compared. However, crude rates and absolute number of deaths are more helpful in determining disease burden and specific needs for services required for a given population. (31) Public health strategies or specific needs for medical service may be determined by the overall disease burden in the total population irrespective of age. Accordingly, concerns should be raised regarding increase in absolute number of deaths and CDR from liver cancer. Particularly, death rates for liver cancer continued to be 3-fold higher for males compared to females throughout the study period, which may require special concern in establishing health care policy. Higher mortalities from liver disease and liver cancer in males have also been revealed in previous studies. (11, 32) This study may have several limitations. First, owing to the nature of a population-based study, we could not collect detailed individual clinical and treatmentrelated data, such as the efficacy of HBV suppression. In addition, the possible contribution of introduction of highly potent antiviral agents, such as entecavir and tenofovir, on changes in mortality was not taken into account in the present study. (4) However, this study aimed to examine temporal trends in liver disease and liver cancer mortality in the HBV-endemic population to obtain broader insights into the population effectiveness of treatments for VH. Second, inaccuracy of death certificates might have influenced the interpretation of our findings. Despite the concern regarding misclassification bias, the cause of death was issued and confirmed by attending physicians on >98% of death certificates in Korea, and thus the possibility of data inaccuracy would be low. Another limitation is that mortality from intrahepatic cholangiocarcinoma, which accounted only for 10% of primary liver cancer, (33) could have been included in mortality from liver cancer. However, the potential sources of misclassification may be mitigated by analyzing trends in mortality of all primary liver cancers, wherein these issues have been assumed to remain relatively constant over time.
In conclusion, although >60% reduction in mortality from liver disease was observed in the past 15 years, the burden of liver cancer has increased in a HBVendemic population. These trends coincided with the exponential use of oral antiviral agents for HBV in the population. Our findings imply that marked decrease in liver disease mortality may increase the life expectancy and number of patients at risk of developing HCC, inadvertently leading to increased HCC incidence and mortality in the population. These findings suggest that, notwithstanding the wide availability of potent antiviral drugs against HBV and HCV and the remarkable reduction in liver disease mortality, the burden of liver cancer would persist for the next several decades. Thus, our findings emphasize the importance of prevention and surveillance of liver cancer, including early initiation of HBV and HCV treatment before progression to cirrhosis and efforts to reinforce HCC surveillance in patients with HBV infection and/or cirrhosis. Furthermore, because it may take over two decades to observe the marked decrease in liver cancer mortality as a result of the universal infantile vaccination program for HBV, novel treatments are urgently required to completely eradicate HBV from infected patients and to prolong the survival of patients with HCC.
